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a b s t r a c t
Human angiogenin (ANG) is an angiogenic molecule and a ribonucleolytic enzyme with signiﬁcant
amino acid sequence identity to pancreatic RNase A, plays a critical role in the establishment and
growth of tumours. An association between ANG and cancer has been observed inmore than 25 clinical
studies to date. In addition, ANG has now been shown to be implicated in Amyotrophic Lateral Sclerosis
(ALS) and Parkinson’s Disease (PD). Structural and biochemical studies so far have showed several
distinguishing features of ANG molecule compared to RNase A and provided details of the putative cell
binding site, active site, nuclear translocation sequence and the roles of residues in binding and cleaving
RNA. A key ﬁnding elucidated from the structural study on ANG is the presence of a ‘blocked’ C-terminus
(part of the active site apparatus) compared with RNase A. Here we report the crystal structure of ANG
with an ‘engineered-loop’ fromeosinophil derivedneurotoxin (a homologue of ANG)whichhas resulted
with local perturbations (conformational ﬂexibility) at the cell binding site and at the C-terminus of the
molecule. This experimental observation will now provide a new avenue to design compounds (potent
inhibitors) through a structure guided drug design route.
C© 2012 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. Open access under CC BY-NC-ND license.1. Introduction
Angiogenin (ANG), also known as ribonuclease 5 (RNase 5), is
an angiogenic molecule that induces neovascularization [1]. It is a
monomeric protein of 14.1 kDa that belongs to the pancreatic ri-
bonuclease A (RNase A; EC 3.1.27.5) superfamily [2]. ANG has similar
catalytic properties to RNase A – it cleaves preferentially on the 3′ side
of pyrimidine and follows a transphosphorylation/hydrolysis mech-
anism [3,4]. The enzymatic activity of ANG, albeit several orders of
magnitude lower than that of RNase A towards conventional RNase
substrates [4], is essential to the angiogenic process [3,5].
The known biological properties of ANG encompass induction of
angiogenesis to stimulating cell proliferation and promoting cell sur-
vival. Under growth conditions, ANG is translocated tonucleus (where
it accumulates in nucleolus) and stimulates ribosomal RNA (rRNA)Abbreviations: RNase A, - ribonuclease A; ANG, - Human angiogenin; EDN -,
eosinophil derived neurotoxin; AEH -, angiogenin–eosinophil derived neurotoxin hy-
brid; RI -, ribonuclease inhibitor
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http://dx.doi.org/10.1016/j.fob.2012.12.003transcription, thus facilitating cell growth and proliferation [6]. Re-
cently it has been established that under stress conditions, ANG accu-
mulates in cytoplasmic compartments andmodulates the production
of tiRNA, a novel class of small RNA that is derived from tRNAand is in-
duced by stress. ANG-mediated tiRNA reprogram protein translation,
save anabolic energy, and promote cell survival [7–10].
Based on biochemical and structural data it has been established
thatANGhas threedistinct functional sites – (a) aputativebinding site
for an unknown receptor, (b) a nuclear localization sequence (NLS),
and (c) a catalytic site. The crystal structure of ANG has revealed
the RNase A fold and the conservation of the catalytic triad – His13,
Lys40 andHis114 [11]. The loop region from Lys60 to Asn68 forms the
receptor-binding site that interacts with a cell surface receptor [12].
Upon binding to the cell surface receptor, ANG is internalized and
translocated to the nucleus [13]. The nuclear translocation process
is mediated by an NLS located between amino acid residues Met30
and Gly34 [14]. The ribonucleolytic activity of ANG [5] is believed to
function in stimulating rRNAtranscriptionafterANG is localized in the
nucleus. It is now ﬁrmly established that all three sites are essential
for ANG to have angiogenic and growth stimulating activities.
Apart fromthe its vascular function, ANGhas alsobeenﬁrmly asso-
ciated with several neurodegenerative conditions. Studies by Green-
way et al. [15] on a large cohort of Amyotrophic Lateral Sclerosis (ALS)
patients (both familial and sporadic) showed for the ﬁrst time that
ANG is implicated in ALS. Since then several other studies worldwide
have also identiﬁed ANG mutations in ALS patients. More recently aean Biochemical Societies.Open access under CC BY-NC-ND license.
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large multi-site study reported the association of mutations in ANG
with ALS as well as Parkinson’s disease (PD) [16,17]. Since the early
reports on ANG associationwith ALS, it has been established that ANG
also possesses neurotrophic andneuroprotective functions [18–20]. A
recent detailed study has provided for the ﬁrst time the structural and
molecular insights into the mechanism of action of human ANG-ALS
variants in neurons [21].
The role of ANG as a tumour angiogenic factor has beenwell docu-
mented. ANGhas been shown to be upregulated in a variety of human
cancers [22]. Elevated serum level and/or enhanced tissue expression
of ANG have been noticed in all types of solid and blood cancers so
far examined. A major mechanism by which ANG induces angiogen-
esis is related to its activity in stimulating ribosomal RNA (rRNA)
transcription [22], a common downstream event of tumour angio-
genesis [23]. In addition, ANG inhibitors have been shown to inhibit
not only ANG-induced angiogenesis but also those induced by other
angiogenic factors such as VEGF, FGF, and EGF [24]. ANG inhibitors
would therefore have a profound effect in inhibiting tumour angio-
genesis. Indeed, ANG inhibitors such as its siRNA [25], antisense [26],
monoclonal antibodies [27], soluble binding proteins [28], enzymatic
inhibitors [29], and nuclear translocation blockers [24,30–32] have all
been shown to inhibit tumour angiogenesis and cancer progression
in various animal models.
We have identiﬁed different types of inhibitors of ANG based on
our structural, mutagenesis and biophysical studies. These will be
used to probe the mechanistic details of ANG. In particular, our aim is
to study the nucleotide inhibitors that target the enzymatic active site
of ANG and also monoclonal antibodies against ANG. The angiogenic
activity of ANG is critically dependent on its enzymatic activity and in-
hibitors that bind to its enzymatic active site also inhibit its angiogenic
activity. Our results from ANG inhibitors have demonstrated proof of
principle, but design of structure-based small molecule nucleotide
inhibitors so far proved to be elusive due to the blockage of the active
site predominantly by Gln117 and the remaining C-terminal segment
of the ANG molecule [11,33–37]. Mutation of Gln117 to Gly/Ala has
shown to increase the ribonucleolytic activity of ANG [38]. However,
the structures of ANG in complex with – (a) a leucine rich, natural
protein inhibitor (50 kDa) of ANG (the ribonuclease inhibitor – RI;
[39]; PDB ID: 1A4Y) and (b) an antibody fragment 26-2F (shown to
inhibit ANG) ([40]; PDB id: 1H0D) have shown signiﬁcant conforma-
tional changes at the cell-binding region of ANG. This region is close
to the active site of ANG and thus it was predicated that induction of
similar conformational change would allow the C-terminal β-strand
(Fig. 1A) to undergo small movement to accommodate the substrate/
inhibitorwithout signiﬁcant alteration in the catalytic property of the
molecule.
In this study we have substituted 84HGGSPWPP91 (a loop that
interacts with RI) of ANG [39] with 86TTPSPQNISN95 of eosinophil-
derived neurotoxin (EDN, also shown to interact with RI) [41] and
constructed an ANG–EDN hybrid (AEH) protein molecule of molec-
ular weight ∼14.5 kDa. EDN is also a member of RNase A super-
family (known as RNase 2), possesses weak ribonucleolytic activity,
antiviral property [42–45] and neurotoxicity [46,47]. Based on our
previous crystal structure analysis of ANG–RI [39] and EDN–RI [41]
complexes it was realistic to assume that AEH molecule would also
retain RI binding property. The experimental data presented in this
report shows that the design of AEH molecule proved to be useful to
study the relationship between the RI binding loop and the structural
changes in the cell-binding region. In addition, the high resolution
crystal structure of the AEH molecule reported here shows that the
‘engineered loop’ causes conformational changes that would perturb
the network of interactions from the nuclear localization sequence
to cell binding region extending to the active site (through inclusion
of the C-terminal segment of the molecule) without altering the en-
zymatic activity. This information may prove useful for the design
of ‘ANG–nucleotide inhibitor complexes’. Similar studies have been
Fig. 1. General features and ﬂexible regions of the AEHmolecule (A–D). (A) Superposi-
tion of AEH [limon (molecule A) and pink (molecule B)] on ANG (pale cyan). Structural
and conformational changes as observed in AEH (limon) vs. ANG (pale cyan); (B) Loop1:
ribonuclease inhibitor (RI) binding region of ANG. Molecule B not shown as the loop
region is disordered; (C) Conformational changes in C-terminal region showing the
displacement of Q119 (Q117 of ANG) away from the active site; (D) Loop2: putative
cell binding site of ANG; and (E) Ribonucleolytic activity of AEH vs ANG. (For interpre-
tation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
reported previously amongst RNase A familymembers and also other
proteins [48–52].
2. Materials and methods
2.1. Cloning, expression and puriﬁcation of AEH
The ANG–EDN hybrid protein (AEH) was prepared using recom-
binant DNA technology where the loop region (84HGGSPWPP91) of
ANG was substituted with the corresponding segment (loop region)
(86TTPSPQNISN95) of EDN. The pET22b(+) Escherichia coli expression
plasmid was provided by Dr. Robert Shapiro, Harvard Medical School
(USA). The protein expression trials were carried out in BL21-DE3
Codon plus (RIPL) cells in the culture medium terriﬁc broth. The
required AEH protein was puriﬁed from inclusion bodies using the
protocol described by Holloway et al. [53]. Purity of the protein was
analysed on an SDS–PAGE.
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2.2. Mass spectrometry
Puriﬁed protein mass of AEH was experimentally conﬁrmed (in
addition to amino acid sequence veriﬁcation) using electrospray ion-
ization mass spectrometry (ESMS) service at University of Bath. Pro-
tein solutions were prepared for mass spectrometry by dilution of a
desalted standard stock solution of protein in water (1 mg/mL, 70
μM) in a 50:50 ratio with HPLC-grade acetonitrile containing 0.1%
formic acid. ESMS was performed in positive ion mode on a QStar XL
System (Applied Biosystems), ﬁtted with a NanoMate (Advion Bio-
sciences) automated nanospray source. A delivery pressure of 0.3 psi
of nitrogen gas and a spray voltage of 1.6 kV were applied to the
sample to generate the nanospray plume. Transformed mass spectra
were calculated by use of the Bayesian protein reconstruct algorithm
provided as part of the MDS Sciex Analyst 1.1 software package.
2.3. RNase activity assay
The activity of AEH protein toward yeast tRNA was determined
by measuring the formation of acid-soluble fragments as described
by Shapiro et al. [4]. Assay mixtures contained 2 mg/mL yeast tRNA
(Sigma), 0.1 mg/mL bovine serum albumin (BSA), and 0.05, 0.1, 0.2,
0.3, 0.4, or 0.5 μM test protein in 33 mM Na-Hepes and 33 mM NaCl,
pH 7.0. After 2 h of incubation at 37 ◦C, reactions were terminated
by the addition of 2.3 volumes of ice-cold 3.4% perchloric acid. The
mixture was then centrifuged at 13,000 rpm for 10 min at 4 ◦C. The
absorbance of the supernatant was measured at 260 nm.
2.4. X-ray crystallography
X-ray diffraction data were recorded (at 100 K) from a single crys-
tal of AEH protein grown in 1.4–2.5MNaCl at 16 ◦C on aMar CCD 165
at station PX 10.1, Synchrotron Radiation Source, Daresbury, UK. No
cryoprotectant was used. The protein was crystallized using hanging-
dropvapourdiffusionmethodat1:1drop ratioofprotein (10mg/ml in
water) to mother liquor. The data were processed and scaled in prim-
itive orthorhombic P212121 space group (2 molecules/asymmetric
unit) using HKL2000 software suite [54] to a 1.76 A˚ resolution. The
data were complete to 91.9% overall with a merging R-value of 0.082
(Table 1). Initial phases for AEH molecule were obtained by molec-
ular replacement method using the human ANG structure (PDB ID:
1ANG; [11]) as the starting model. The software used for molecular
replacement trials were MOLREP [55] and PHASER [56]. The resul-
tant model of AEH protein was taken through a rigid body reﬁnement
(after deletion of the substituted loop region (84HGGSPWPP91)). The
Rcryst and Rfree values after the ﬁrst round of rigid body reﬁnement
were 0.491 and 0.505 respectively. Further model building and re-
strained reﬁnement were carried out using COOT [57] and PHENIX
[58] respectively. During this process all the side chain atoms were
placed in the electron density map, the substituted loop region was
modelled and ﬁtted into the electron density using Fourier difference
density map. Finally the water molecules and chloride ions (from the
crystallization medium) were modelled into the structure. The struc-
ture was reﬁned to a ﬁnal Rcryst and Rfree value of 0.239 and 0.285
respectively. There are a total of 83 water molecules and 4 chloride
ions in the ﬁnal structure. A few regions of the AEH structure exhibit
a high degree of conformational ﬂexibility (see below). The structure
was validated usingMolProbity validation tool [59,60]. Therewere no
residues in the disallowed region of the Ramachandran plot. Crystal-
lographic data statistics are summarized in Table 1. All ﬁgures were
drawn with PyMOL (DeLano Scientiﬁc LLC, San Carlos, CA, USA) and
rendered with POV-ray.
Table 1
X-ray data collection and reﬁnement statistics.
Space group Orthorhombic – P212121
Cell dimensions a = 38.4 A˚; b = 54.7 A˚; c = 94.7 A˚
Resolution range (A˚) 50–1.76
Rsymm
a (outer shell) 0.082 (0.299)
I/σI (outer shell) 14.5 (2.9)
Completeness (outer shell) % 91.9 (65.8)
Total number of reﬂections 230,027
Number of unique reﬂections 20,481
Redundancy (outer shell) 4.8 (2.5)
Wilson B-factor (A˚2) 29.0
Rcryst
b/Rfree
c 0.239/0.285
Average B-factor (A˚2)
Overall 34.7
Protein (chain A, B) 33.6, 35.5
Chloride ion 36.9
Solvent 37.1
RMS deviation
Bond length (A˚) 0.007
Bond angle (◦) 1.012
Ramachandran plot statistics
Favoured (%) 97.71
Additional favoured (%) 2.29
PDB ID 4B36
a Rsymm = Σh Σi |I(h) − Ii(h)|/Σh Σi Ii(h), where Ii(h) and I(h) are the ith and the mean
measurements of the intensity of reﬂection h, respectively.
b Rcryst = Σh |Fo − Fc|/ΣhFo, where Fo and Fc are the observed and calculated structure
factor amplitudes of reﬂection h, respectively.
c Rfree is equal to Rcryst for a randomly selected 5.0% subset of reﬂections not used in the
reﬁnement.
3. Results and discussion
3.1. General features
All ANG structures determined so far [11,33–37] have a highly
conserved RNase A fold – a characteristic feature of proteins belong-
ing to this family (Fig. 1A). Brieﬂy, the RNase A fold (a kidney-shaped
molecule) consist of α and β secondary structure elements form-
ing the core of the molecule connected by loop structures. In ANG
molecule there are three α-helices, seven β-strands and a 310 helix
(at the C-terminus) (Fig. 1A). The core of the molecule is stabilized by
three disulphide bridges. The catalytic site [formed by residues His13
(α1), Lys40 (loop connecting α2 and β1) and His114 (β7)] is located
on the concave structure of themolecule. TheNLS residues lie on helix
α2, RI binding residues in the loop connectingβ4 andβ5, and receptor
binding site includes the loop connecting helix α3 and strand β2 and
β2. The AEH structure retains these features in both molecules of the
asymmetric unit but displays signiﬁcant conformational ﬂexibility in
the loop regions of the molecule (Fig. 1B–D, see below).
Comparison of native ANG structure [11] with the AEH structure
(present study) result with a root mean square deviation of 1.34
and 1.71 A˚ (Cα atoms) for molecule A and B (for the two copies in
the hybrid molecule in the asymmetric unit) respectively. The active
site of AEH molecule comprises the catalytic triad residues His13,
Lys40 and His116 (His13, Lys40 and His114 in ANG) which form links
with residues Gln12, Asn43, 117Leu-Asp-Gln119 (115Leu-Asp-Gln117
in ANG) either through direct hydrogen bonding or through a water-
mediated network. A detailed analyses of the catalytic site of AEH
against a few members of the RNase A superfamily determined at
atomic resolution – the prototypemolecule RNaseA (PDB: 2E3W, 1.05
A˚ resolution [61]), EDN (PDB: 1GQV, 0.98 A˚ resolution [62]), and ANG
(PDB: 4AOH, 1.04 A˚ resolution [21]) showed the presence of a highly
conserved solvent network involving four water molecules (labelled
as 1–4 in Fig. 2A–E). It is likely that these solvent molecules might
play an important role in substrate recognition and/or binding. For
example, in an ANG-ALS variant Gln12Leu structure [33], the enzyme
lost both its ribonucleolytic and angiogenic properties (required for
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Fig. 2. Stereo representation of conserved solvent network in (A) AEH – molecule A;
(B) AEH – molecule B; (C) ANG; (D) EDN (solvent molecule equivalent to 4 or chloride
ions are coloured inmagenta) and (E) RNase A. Conservedwatermolecules are labelled
as 1–4. Chloride ions are coloured in orange. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
the action of ANG), where themutation fromGln to Leu perturbed the
network of interactions (including the conserved solvent molecules)
involving the catalytic residue His13.
Fig. 3. Cartoon representation of AEH molecule docked to ribonuclease inhibitor (RI
– PDB id: 1A4Y). In pale cyan is native ANG, light brown is ANG bound to RI (PDB
ID: 1A4Y) and in limon is AEH. There are no large conformational changes observed
between native ANG and ANG bound to RI. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
3.2. Conformational ﬂexibility
3.2.1 RI-binding loop
A large movement in the engineered loop region
(86TTPSPQNISN95) was observed where residue Pro88 under-
goes a major shift of ∼90◦ in comparison to its position in the native
ANG structure (Figs. 1B, 3). In the ANG structure this region (also
called as the RI-binding loop) is involved in binding to RI as observed
in the crystal structure of ANG–RI complex [39] through several
main- and side-chain interactions. In both the molecules of AEH,
the RI-binding loop adopts similar conformation, but signiﬁcantly
different from that observed in the ANG–RI complex or in the native
ANG structure (Figs. 1B, 3). Hence we predict that this change would
perturb RI binding even though AEH molecule seems to possess
similar ribonucleolytic activity as native ANG (Fig. 1E). The Ki value
of RI for ANG and EDN are 7.1 × 10−16 M [63,64] and 6.7 × 10−15
M [41] respectively. The structural superposition of native EDN
(PDB: 1GQV [62]), EDN-RI (PDB: 2BEX [41]), native ANG (PDB: 4AOH
[21]), ANG–RI (PDB: 1A4Y [39]) against AEH molecules show that
the conformational changes observed are unique to AEH molecules.
However, the nuclear translocation sequence 31RRRGL35 in the AEH
molecule does not undergo any conformational change and retains
similar conformation as in native ANG.
3.2.2 Cell receptor binding loop
The second structural changewas observed at the secondary struc-
tural element β2 strand of ANG, which transformed to a loop region
(Gly62–His65) in the AEH structure (Fig. 1A, D), and the loop connect-
ing the strand β2 and α3 could not be modelled due to lack of visible
electron density. This region is a part of the putative cell binding seg-
ment of ANG [12,65,66]. This segment has shown to undergo signif-
icant conformational change by adopting an extended conformation
based on the structural details observed from the crystal structures
of ANG–RI [39] and ANG–Fab antibody [40] complex reported previ-
ously from our laboratory.
3.2.3 C-terminal region
An unexpected conformational ﬂexibility was observed at the C-
terminal segment of AEH structure starting from Leu117 (Leu115
based on ANG numbering). This structural movement at the active
site displaces the Gln119 of AEH (Gln117 of ANG) by ∼90◦ inwards
(away from the active site) (Figs. 1C, 4). In the most predominantly
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Fig. 4. The C-terminal pocket of AEH molecule. (A) Chloride ion bound at the active
site of AEH and (B) Superposition of both the molecules of AEH in the asymmetric
unit. One of the molecule of AEH (limon) shows the position of Q119 overlapping with
the chloride ion from the second molecule of AEH (pink). (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
Fig. 5. Surface potential diagram – (A) for ANG and (B, C) for AEH molecule. In (B)
the surface charge near the C-terminal region (active site) is similar to ANG, but in
(C) the C-terminal region undergoes a conformational change and forms a long groove
where the substrate possibly binds. Differences are due to the changes observed in the
conformations of the loop regions 1 and 2 for the AEH molecule. (D) An oligomer of
DNA backbone (coloured in red) (10-mer, with only phosphate and ribose moieties)
docked on to the AEHmolecule B. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
observed state (as observed in the native structure of ANG [11]), the
side chain atoms OE1 and NE2 of Gln117/Gln119 of ANG/AEH re-
spectively are involved in direct hydrogen bonding interactions with
active site residue His13 and Thr44, thus blocking substrate binding
and the availability of His13 and Thr44 for catalysis. As observed in
one of the molecule of AEH structure, the displacement of Gln119
(Gln117 of ANG) opens the active site and enhances the binding of
the substrate. The side chain atoms OE1 and NE2 of Gln119 (Gln117
of ANG) of AEH interact with Arg103, Arg104 and Val106 through
hydrogen bonding interactions. A chloride ion (due to high concen-
tration ofNaCl used in crystallizationmedium)was bound in theplace
of Gln119 following the displacement of Gln119 (Fig. 4). We tested
the AEH protein for its catalytic activity in the presence of 0.1–2.5 M
NaCl concentration and did not observe any alteration in the RNase
activity and hence conclude that the observed chloride ion at this site
has no direct role in catalysis. Comparison of electrostatic potential
between ANG and the AEH (in both molecules) (Fig. 5) clearly shows
the apparent change in potential charge at the active site due to the
conformational change at the C-terminal region – resulting in larger
basic surface area for the nucleotide substrate to bind. Thus for the
ﬁrst time the AEH structure has provided a glimpse of conformational
ﬂexibilities at the functional regions of the parent molecule.
4. Conclusions
We have compared the solution structure of ANG (determined by
nuclear magnetic resonance) (PDB: 1AWZ [67]) with the high reso-
lution structure of ANG in the crystalline state (determined by X-ray
crystallography, PDB: 4AOH [21]) and found that the loop regions
retain similar conformation in both structures. Thus, substitution
of ANG loop region (84HGGSPWPP91) by EDN amino acid residues
(86TTPSPQNISN95) in the AEH structure seem to have resulted in con-
formational changes at the functional regions of the molecule (that
are observed for the ﬁrst time in the ANG structure determined so
far). The hybrid molecule AEH retains the full complement of ribonu-
cleolytic activity and do not exhibit any perturbation at the catalytic
centre (involving the catalytic triad). However, signiﬁcant movement
of the cell-binding segment of AEH molecule was evident. In addi-
tion, the C-terminus of AEH molecule (in one copy of the asymmetric
unit) adopts a non-obstructive conformation (hitherto unseen) in the
hybrid molecule. These observations will have implications for the
future design of ANG nucleotide based inhibitors.
The structural ﬂexibility observed in the AEH molecule gives us
some insight about the network of interactions involving the NLS
and the cell-binding sites through the active site and C-terminal seg-
ments. These changes appear to be a sequential event during catalysis.
The perturbation of the C-terminus moves the Gln119 residue away
from its obstructive state and Arg121 points outwards – leading to
an enhanced surface accessibility and gain in net positive charge. In
order to assess the feasibility of substrate binding, we have docked an
oligomer of DNA backbone (containing only the ribose and the phos-
phatemoiety) to this cavity (Fig. 5D). The length of the DNA backbone
used was a 10-mer. From the modelling studies we predict that Arg5,
His8, Gln12, Lys40, Asp41, Lys82, His116 (equivalent to H114 of ANG)
and Arg124make hydrogen bonding interactions with the phosphate
and ribose molecules.
Database
The atomic coordinates and structure factors for AEH (with code
4B36) have been deposited in the Protein Data Bank, Research Col-
laboratory for Structural Bioinformatics, Rutgers University, New
Brunswick, NJ (http://www.rcsb.org/).
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